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The aims of the present research were to characterize the plasma and brain concentration– time profiles of lamotrigine after its acute
administration and to establish the relationship between these profiles and the anticonvulsant effect of lamotrigine in rats. Adult male Wistar
rats were given 10 mg/kg of lamotrigine intraperitoneally. The lamotrigine profiles in plasma and brain were determined at predetermined
times over 120-h post-dose. The anticonvulsant profile against maximal electroshock seizure stimulation was determined over 48 h after
dosing. After injection, lamotrigine rapidly appeared in both plasma and brain, suggesting ready penetration of the blood–brain barrier. A
linear relationship was established between lamotrigine plasma and brain levels. A linear relationship was also defined between lamotrigine
brain levels and the anticonvulsant response. The correspondent plasma levels were also well correlated with the anticonvulsant effect from
the moment that the plasma–brain system had reached equilibrium.
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Lamotrigine (3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-
triazine) is a new generation antiepileptic drug which has
been shown to be effective against partial and secondarily
generalized tonic–clonic seizures, either as adjunctive treat-
ment in patients with refractory epilepsy or when received
as monotherapy (Goa et al., 1993). Actually, lamotrigine
exhibits a relatively broad spectrum of efficacy, against
some common seizure types, such as partial seizures (with
or without secondary generalization), primarily generalized
tonic–clonic seizures, absence seizures and drop attacks. Its
efficacy in myoclonic seizures and infantile spasms is still
unclear (Perucca, 2002).
The first mechanism of action of lamotrigine referred to
in the literature was similar to that proposed for carbama-
zepine and phenytoin and involved the stabilization of the
presynaptic membrane through the blockade of the voltage-
sensitive Na+ channels, which resulted in the inhibition of
excitatory neurotransmitter release, particularly glutamate0014-2999/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejphar.2003.09.065
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E-mail address: acfalcao@ff.uc.pt (A. Falca˜o).and aspartate (Goa et al., 1993). More recently, it was
proposed that lamotrigine also inhibits high voltage-activat-
ed Ca2 + currents, interacting consequently with the vesic-
ular release of transmitters (Waldmeier et al., 1995; Stefani
et al., 1996).
The use of lamotrigine in clinical practice is reasonably
well tolerated by patients (Richens, 1994). However, the
resulting benefits of its administration are subject to a more
complex evaluation, given the considerable inter-patient
variability observed in relation to the dosage required to
obtain an appropriate therapeutic response. A notional target
range of 1–4 mg/l was initially proposed, but subsequent
observations have indicated that some patients may tolerate
much higher therapeutic concentrations (>10 mg/l) without
clinical toxicity. A linear relationship appears to exist be-
tween the doses of lamotrigine administered and the respec-
tive plasma concentrations. Thus, the difficulty lies in the
establishment of a relationship between lamotrigine plasma
levels and the induced pharmacological response. In the light
of current knowledge, it seems evident that, to assess a
relationship between plasma concentration and clinical effect
of lamotrigine, further studies are required (Kilpatrick et al.,
1996; Bartoli et al., 1997; Morris et al., 1998).
As with all antiepileptics, lamotrigine needs to cross
the blood–brain barrier to exert its therapeutic effect.
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levels requires the assessment of the drug concentration
at the neuronal sites of action. Afterwards, the character-
ization of the experimental anticonvulsant profile of
lamotrigine is important in the evaluation of its pharma-
cological response. Accordingly, the aims of the present
research were to define the plasma and brain concentra-
tion–time profiles of lamotrigine after its administration
as a single intraperitoneal dose and to establish the
relationship between these profiles and the anticonvulsant
effect of lamotrigine against maximal electroshock seiz-
ures in rats. The analysis of the results obtained from
these studies is thought to bring some light to the
assessment of the relationship between plasma concentra-
tion and clinical effect of lamotrigine.2. Materials and methods
2.1. Animals
The studies were carried out on adult male Wistar rats,
weighing 250–320 g (Harlan Iberica, Barcelona, Spain).
The rats were housed in a local bioterium with a
controlled 12-h light/dark cycle. Animals were allowed
free access to food and water until the experiments,
performed at 22–23 jC. Animal experimentation in this
study was conducted in accordance with the European
guidelines for the care and use of laboratory animals (86/
609/EEC) and the project was approved by the Portu-
guese Veterinary General Division.
2.2. Drugs
Lamotrigine, lamotrigine isethionate and the internal
standard (3,5-diamino-6-(2-methoxyphenyl)-1,2,4-triazine
(BW725C78) were kindly provided by Wellcome Re-
search Laboratories (Cardiff, UK). Ketamine hydrochlo-
ride (7.7 mg/kg) (Pfizer Laboratories, Seixal, Portugal)
and chlorpromazine (2.3 mg/kg) (Vito´ria Laboratories,
Amadora, Portugal) were used to anaesthetise the animals
before sample collection. Oxibuprocaine chloride
(Oftalder, Oeiras, Portugal) was used to anaesthetise the
rats’ eyes. Reagents and columns used in the chromato-
graphic analysis were purchased from Merck (Darmstadt,
Germany).
2.3. Experimental design
For the characterization of systemic and central lamo-
trigine profiles in the rat, a group of 45 animals was
given 10 mg/kg of lamotrigine intraperitoneally in an
aqueous solution of lamotrigine isethionate (Castel-Branco
et al., 2002). Sample collection occurred at predetermined
times. Subgroups of five animals were used at each data
point. Blood samples were obtained by open cardiacpuncture and collected in citrated tubes at 7.5, 15 and
30 min, 2-, 12-, 24-, 48-, 72- and 120-h post-dose.
Immediately afterwards, the animals were decapitated
and the brains removed to be homogenized in 5 ml of
phosphate buffer (pH = 7.4) per g of tissue at 4 jC. Blood
collection was carried out under anaesthesia injected intra-
muscularly 10 min before the referred to procedure. Plasma
and whole brain homogenates were immediately frozen at
 25 jC until analysis.
For the assessment of the anticonvulsant profile of
lamotrigine in the rat following a 10 mg/kg intraperito-
neal dose, a second group of animals was used. Maximal
electroshock seizure stimulation was applied through
bipolar corneal electrodes from an electroshock apparatus
(Ugo Basile ECT unit 7801) at an intensity sufficient to
elicit tonic hindlimb extension in f 100% of the control
animals (current: 150 mA; frequency: 60 Hz; pulse
width: 0.6 ms; duration: 0.2 s) (Lo¨scher et al., 1991).
Immediately before placement of the electrodes, a drop of
the anaesthetic oxibuprocaine chloride was introduced
into the rat eyes. Only the animals that consistently
exhibited the tonic hindlimb extensor component of
maximal electroshock seizure during three trials on sep-
arate days, while unmedicated, were used (Swinyard et
al., 1952; Browning and Nelson, 1985; Ramzan and
Levy, 1989). Eight animals per group were tested once
at a predetermined time after drug injection: 15 and 30
min, 1-, 2-, 4-, 8-, 12-, 24-, 36- and 48-h post-dose. The
anticonvulsant activity of lamotrigine was determined as a
quantal endpoint (i.e. the presence or absence of tonic
hindlimb extension). The number of animals protected
against maximal electroshock seizure stimulation was con-
verted into a percentage (eight animals protected = 100%
protected).
2.4. Lamotrigine quantification
Lamotrigine levels in plasma and brain homogenate
were determined according to a high-performance liquid
chromatography (HPLC) method, previously described
(Castel-Branco et al., 2001). Briefly, to 1 ml of plasma,
100 Al of a 40 mg/l internal standard solution, 1 ml of 2
M NaOH and 5 ml of ethyl acetate were added. After
centrifugation, the upper organic layer was transferred to
a clean 10-ml conical glass tube and evaporated to
dryness. The brain homogenate extraction included a
previous deproteinization step: to 1 ml of brain homog-
enate, 100 Al of a 20 mg/l internal standard solution and
100 Al of a 20% trichloroacetic acid solution were added.
After centrifugation, the supernatant was transferred to a
10-ml glass tube and submitted to a liquid–liquid extrac-
tion into ethyl acetate after basification, as described for
plasma. The residues obtained were reconstituted with
200 Al of mobile phase and injected into the HPLC
system. Chromatographic separation was carried out on a
LiChrospher 100 RP-18 (5 Am) LiChroCART 125-4
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35.0% methanol, 64.7% 0.1 M potassium dihydrogen
phosphate solution and 0.3% triethylamine, was pumped
at a flow rate of 1.0 ml/min. The detector was set at 306
nm. The linearity was demonstrated over a range of 0.1–
15.0 mg/l for plasma and 0.1–5.0 mg/l for brain homog-
enate, with a lamotrigine detection limit of 0.01 and 0.02
mg/l in plasma and brain homogenate, respectively. The
results of the method validation were all in accordance
with international recommendations, providing the suit-
ability of the method for lamotrigine quantification in
these biological matrices.3. Results
3.1. Lamotrigine plasma and brain homogenate concen-
tration–time profiles
Plasma and brain homogenate concentrations of lamo-
trigine following a single 10 mg/kg intraperitoneal dose are
presented in Table 1. The experimental peak plasma value
was considered achieved at 15-min post-dose, despite the
fact that no major differences had been found between the
plasma levels measured at 15, 30 min and 2-h post-dose
(analysis of variance, P>0.05). Brain homogenate experi-
mental concentrations peaked somewhat later than plasma
levels, between 30 min and 2 h after the intraperitoneal
injection. After peak values, both lamotrigine plasma and
brain levels decreased exponentially. The lamotrigine brain
homogenate levels determined at 120-h post-dose were notTable 1
Plasma and brain homogenate concentrations of lamotrigine and its
anticonvulsant effect against maximal electroshock seizures following a
single 10 mg/kg intraperitoneal dose of lamotrigine in the rat
Time after Plasma levels (mg/l) Brain levels (mg/l) Protection
administration (h)
Cexperimental
b Cfitted
c Cexperimental
b Cfitted
c (%)
a
0.125 2.98F 0.364 3.22 0.44F 0.244 0.51 –
0.25 5.42F 0.798 4.36 1.02F 0.301 0.87 25.0
0.5 4.99F 1.099 4.89 1.64F 0.255 1.29 62.5
1 – 4.91 – 1.57 87.5
2 4.83F 0.916 4.79 1.67F 0.283 1.63 100.0
4 – 4.56 – 1.57 100.0
8 – 4.13 – 1.45 87.5
12 3.44F 0.488 3.73 1.21F 0.205 1.34 62.5
24 2.98F 0.545 2.77 1.06F 0.290 1.05 12.5
36 – 2.05 – 0.83 12.5
48 1.29F 0.373 1.52 0.57F 0.115 0.65 0.0
72 1.03F 0.191 0.83 0.44F 0.156 0.40 –
120 0.25F 0.133 0.25 – 0.15 –
a Percentage protection against maximal electroshock seizure stimula-
tion (eight animals).
b MeanF standard deviation (five animals).
c Concentration obtained from the biexponential equation used to fit the
experimental values (Yamaoka et al., 1981): Cplasma = 5.039e
-0.025.t–
5.039e-8.203.t and Cbrain = 1.699e
-0.020.t–1.699e-2.908.t.considered because they were below the limit of quantifi-
cation of the analytical technique (0.1 mg/l).
3.2. Lamotrigine brain/plasma relationship
After the absorption phase (z 0.5-h post-dose), a linear
correlation was established between the mean lamotrigine
values determined in plasma and in brain homogenate, with
r2 = 0.997.
The degree of drug uptake from plasma into brain
tissue was estimated from the ratio of the drug concen-
tration in brain homogenate over the plasma concentration
(Cbrain homogenate/Cplasma). The mean calculated ratio value
from all measurements between 0.5- and 72-h post-dose was
0.38F 0.097 (meanF standard deviation). In order to make
possible the comparison of this uptake between different
experimental studies, the brain homogenate concentration
values, expressed by Ag/ml (5 ml of phosphate buffer per g
of brain tissue), were converted into values expressed by Ag/
g of brain tissue. This conversion was performed by assum-
ing that brain specific gravity is 1.0 g/ml (Adusumalli et al.,
1993; Deguchi et al., 1995). The mean calculated brain/
plasma concentration ratio value between 0.5- and 72-h post-
dose was, therefore, 2.29F 0.580.
3.3. Lamotrigine anticonvulsant profile
The anticonvulsant responses of lamotrigine evaluated
over 48 h following a single 10 mg/kg intraperitoneal dose
are presented in Table 1. Lamotrigine showed effectiveness
within 15 min—the shortest time tested—with maximal
anticonvulsant activity between 2- and 4-h post-dose. A
very considerable protection (>50%) persisted up to 12 h,
but at 48-h post-dose no more protection was detected.
3.4. Lamotrigine anticonvulsant effect–plasma and brain
concentration relationships
Time courses of lamotrigine plasma and brain homoge-
nate concentrations and its anticonvulsant effect against
maximal electroshock seizures are reported together in
Fig. 1.
To define the kind of relationship established between the
anticonvulsant effect and the matching brain concentrations,
the values of the lamotrigine anticonvulsant responses were
plotted against the corresponding lamotrigine brain levels,
as shown in Fig. 2(B). The regression analysis performed
established a linear relationship between the lamotrigine
brain concentrations and the respective anticonvulsant
effects, by revealing a coefficient of determination (r2) of
0.937.
Relative to the effect–plasma concentration relationship,
the regression analysis presented a r2 of 0.684 (Fig. 2(A)).
However, when the regression analysis was performed after
rejecting the two first data points, a strong correlation was
observed between lamotrigine plasma levels and the phar-
Fig. 2. Anticonvulsant responses to lamotrigine, expressed as the % of rats protected, versus lamotrigine plasma levels (A) and lamotrigine brain homogenate
levels (B) following a single 10 mg/kg intraperitoneal dose of lamotrigine in the rat (sampling time from 0.25 to 48 h after administration).
Fig. 1. Lamotrigine anticonvulsant effect against maximal electroshock seizures (right vertical axis) versus time profile and plasma and brain homogenate
lamotrigine concentration (left vertical axis) versus time biexponential profiles following a single 10 mg/kg intraperitoneal dose of lamotrigine in the rat.
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48 h after administration).4. Discussion
The present study was designed and performed bearing
in mind the difficulty that still currently exists in the
establishment of a relationship between lamotrigine plasma
levels and the induced pharmacological response. In spite of
the microdialysis study carried out by Walker et al. (2000),
the present data represent additional information for the
characterization of lamotrigine neuropharmacokinetics in
rats, since it is important to compare the extracellular with
the total brain levels of the drug to define the pharmaco-
logically relevant concentration. Additionally, as far as we
are aware, the present research represents the first report on
the temporal inter-relationship of lamotrigine plasma and
brain concentrations and its anticonvulsant activity evaluat-
ed against maximal electroshock.
A dose of 10 mg/kg was chosen because this dose had
previously been found to be within the anticonvulsive range
in the rat (Wheatley and Miller, 1989). Also, with this dose,
the plasma concentrations achieved were similar to the
concentration range that had been proposed for epileptic
patients (Morris et al., 1998).
After intraperitoneal administration, lamotrigine rapidly
appeared in plasma (peak value at 0.25 h), demonstrating
rapid absorption from the peritoneal cavity. In addition,
lamotrigine quickly appeared in the brain (peak value
between 0.5 and 2 h), suggesting ready penetration of the
blood–brain barrier. These observations are comparable to
those previously reported by Walton et al. (1996) and
Walker et al. (2000). After peak values, a monoexponential
fall was observed both in lamotrigine plasma and brain
concentrations. Taking into account the parallel patterns
observed in lamotrigine plasma and brain profiles—demon-
strated in this study by the linear relationship established
between drug in plasma and drug in brain—it can be
assumed that the distribution of lamotrigine from plasma
into brain tissue is only limited by blood flow, suggesting
that lamotrigine crosses the blood–brain barrier by simple
diffusion. The parallel decline of lamotrigine concentrations
in the brain and those measured in plasma also suggests no
excessive retention of the drug in the brain tissue, which is
consistent with the findings of Parsons et al. (1995) when
they state that the rate of lamotrigine elimination from
tissues is comparable to that from plasma, with the excep-
tion of the kidney and melanin-containing tissues.
The calculated brain/plasma concentration ratios rose
rapidly to an equilibrium, providing a measure of the
capacity of the brain to balance with plasma and to maintain
lamotrigine brain concentrations comparable to those in the
circulation. The results obtained showed that the lamotrigine
brain tissue concentrations are approximately twofold
higher than those in plasma. Despite the different proce-dures involved, the ratio found is in accordance with those
reported before (Parsons et al., 1995; Walton et al., 1996).
Such a good distribution of lamotrigine in the brain is
certainly a result of the basic and lipophilic properties of
the molecule, which permits it to cross the blood–brain
barrier easily and to have high affinity to the brain tissue.
Additionally, lamotrigine had effect in the maximal
electroshock seizure test, which reflects its clinical efficacy
against generalized tonic–clonic seizures (Lo¨scher et al.,
1991). The results obtained revealed that the intraperitoneal
administration of 10 mg/kg of lamotrigine considerably
protects rats from maximal electroshock induced-seizures
in a time-range of 0.5–12-h post-dose. This profile is
coherent with a rapid onset of lamotrigine activity as well
as with a long duration of action of the drug, as reported
before (Miller et al., 1986). The absence of protection at 48-
h post-dose was in conformity with the low lamotrigine
levels determined at that time either in the plasma or in the
brain. Because no more protection was observed at 48 h after
dosing, the study of the anticonvulsant response was ended
at that time-point, although the plasma and brain sampling
times were prolonged until 120-h post-dose (when the
determined brain lamotrigine levels felt below the limit of
quantification of the analytical technique).
Lastly, the experimental design performed provided an
opportunity for assessment of the kind of relationship
established between lamotrigine plasma or brain levels
and the anticonvulsant response. The results obtained
revealed that the drug in the brain correlates well with the
anticonvulsant response: maximal anticonvulsant activity
corresponded to the highest lamotrigine brain levels
achieved. Interestingly, an apparent dissociation of anticon-
vulsant effect from brain concentrations in the period
between 12 and 24 h was observed. In fact, the percentage
of rats protected against maximal electroshock is 62.5% at
12 h and it is only 12.5% at 24 h, while over that time, the
falling brain concentrations are of the order of only about
0.2 mg/l (Table 1). Unfortunately, in the absence of addi-
tional microdialysis studies, it cannot be clarified if this
situation reflects differences in the ratio unbound/bound
drug within the brain over that period or if it may be
attributed to some sort kind of tolerance. Nevertheless, this
situation does not impede the characterization of the rela-
tionship between drug in brain and anticonvulsant response
as being a straight line. Relative to the effect–plasma
concentration relationship, the regression analysis per-
formed revealed that a linear relationship can only be
established after rejecting the two first data points. In fact,
as shown in Table 1, the relatively high plasma levels of
lamotrigine found in the first sampling hour did not corre-
spond to high lamotrigine brain levels, since the drug had
not yet enough time to cross the blood–brain barrier and
reach equilibrium. Therefore, taking into account the fact
that lamotrigine acts in the central nervous system, the
relatively high lamotrigine plasma levels found in the first
sampling hour could not correspond to high maximal
M. Castel-Branco et al. / European Journal of Pharmacology 482 (2003) 163–168168electroshock protection. Consequently, the results obtained
revealed that the drug in the plasma correlates well with the
anticonvulsant response only after the plasma–brain system
had reached equilibrium.
In conclusion, the results obtained in this study demon-
strated the existence of a linear relationship between lamo-
trigine in the plasma and lamotrigine in the brain (since the
system has reached equilibrium) in addition to a linear
relationship between lamotrigine in the brain and the anti-
convulsant response obtained. So, it might be suggested that
the plasma levels of lamotrigine are good indicators of the
concentration of lamotrigine at its site of action and, conse-
quently, that they are strongly correlated with the anticon-
vulsant effect of lamotrigine. However, since there is no
clinical evidence of such a direct relationship, other justifi-
cations for the existing difficulty in the establishment of a
relationship between the dose of lamotrigine administered
and the clinical effect observed should be made. To some
extent, the large inter-patient variability observed in dosage
requirements is related to wide differences in lamotrigine
pharmacokinetics, especially among patients also receiving
antiepileptic drugs that inhibit or induce lamotrigine metab-
olism. Besides these drug interactions, the inter-patient var-
iability may also be explained by age-dependent changes in
drug disposition, disease states, seizure type or genetic factors
(e.g., an over-expression of P-glycoprotein in epileptic tissue
(Lo¨scher and Potschka, 2002; Potschka et al., 2002)). So, the
present results suggest further studies to a better understand-
ing of this new generation antiepileptic drug.Acknowledgements
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